Klen, E.E.,
Nikitina, I.L.,
Khaliullin, F.A.,
Shepilova, S.O.,
Nikitina, E.A.,
Gaisina, G.G.,
Samorodov, A.V.,
Pavlov, V.N. (2024) , tumorigenicity, reproductive
effects, irritating
effects), low toxicity (class IV-V), and acceptable oral
Balkhiyarova, Z.,
Luciano, R.,
Kaakinen, M.,
Ulrich, A.,
Shmeliov, A.,
Bianchi, M.,
Chioma, L.,
Dallapiccola, B.,
Prokopenko, I.,
Manco, M. (2022) between 2 and 19 years. We defined GRS for T2D, FG and FI and tested their
effects on glycaemic traits
FENG, C.,
GONG, R.,
ZHENG, Q.Y.,
YANG, G.G.,
HE, M.Y.,
LEI, H.,
LI, X.D.,
ZHANG, L.,
XU, Z.H.,
LIU, S.Z.,
YU, M.X.,
MA, T.S.,
GAO, M.Q.,
BAMBA, D.,
IDIYATULLINA, E.T.,
ZAGIDULLIN, N.SH.,
PAVLOV, V.N.,
XU, C.Q.,
YUAN, Y.,
YANG, L. (2019) therapeutic strategies for several cancers. However, the combination
effects of ATO and blue LED on tumor